RECRUITING

Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults with Borderline Personality Disorder

Talk to us

Conditions

Borderline Personality DisorderfMRI neurofeedbackmindfulness

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to test the ability of mindfulness-based real time functional magnetic resonance imaging (fMRI) neurofeedback (mbNF) to increase the benefits of evidence-based psychotherapy for adults with Borderline Personality Disorder (BPD).

Official Title

Mindfulness-based Neurofeedback to Augment Dialectical Behavior Therapy (DBT) for Adults with Borderline Personality Disorder (Aim 1)

Quick Facts

Study Start:2025-03-07
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06446765

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * age 18-60,
  2. * be able to provide written informed consent,
  3. * meet criteria for BPD on semi-structured clinical interview,
  4. * able to plan to keep any prescribed medications and psychotherapy constant during the study
  5. * fluent in English.
  1. * current DBT psychotherapy outside the study
  2. * lifetime primary psychotic disorder or Bipolar I disorder
  3. * developmental disorder (e.g. autism)
  4. * history of learning disorder
  5. * moderate or severe substance use disorder in the last 6 months
  6. * active suicidal ideation with intent or plan in the past 3 months
  7. * history of major medical or neurologic disorder
  8. * MRI contraindications, including pregnancy
  9. * poor performance on reading task (WRAT \> 11 errors)
  10. * newly prescribed medications in the past 8 weeks
  11. * daytime sedating medications (e.g. benzodiazepines, opiates, sedating neuroleptics)
  12. * any scheduled daily benzodiazepines
  13. * change in psychotherapy type or frequency in the past 12 weeks.
  14. * At the discretion of the study PI

Contacts and Locations

Study Contact

Sarah K Fineberg, MD PhD
CONTACT
203-974-7265
sarah.fineberg@yale.edu

Principal Investigator

Sarah K Fineberg, MD PhD
PRINCIPAL_INVESTIGATOR
Yale University

Study Locations (Sites)

Connecticut Mental Health Center
New Haven, Connecticut, 06519
United States

Collaborators and Investigators

Sponsor: Yale University

  • Sarah K Fineberg, MD PhD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-03-07
Study Completion Date2026-12

Study Record Updates

Study Start Date2025-03-07
Study Completion Date2026-12

Terms related to this study

Keywords Provided by Researchers

  • fMRI neurofeedback
  • mindfulness

Additional Relevant MeSH Terms

  • Borderline Personality Disorder